[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573698":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":29,"centralContacts":35,"locations":44,"responsibleParty":59,"collaborators":29,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":29,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":29,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":29,"overallStatus":83,"whyStopped":29,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Sohag University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Polidacanol","ACTIVE_COMPARATOR","will receive intralesional injection of (polidacanol 3% (Aethoxysklerol 3%,60mg\u002F ml ampoule, kreussler pharma, Germany) During the study, the dosage of the drug and frequency of treatment will be uniform in all patients. The base of each wart will inject until the lesion blanch using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until the resolution of warts or for a maximum of 6 sessions.",[13],"Drug: polidacanol 3%",{"label":15,"type":10,"description":16,"interventionNames":17},"Candida","will receive intralesional injection of candida antigen at a dose of 0.2 ml. Each treatment will inject into the largest wart using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until complete clearance of warts or for a maximum of 6 treatment sessions.",[18],"Biological: candida antigen",{"label":20,"type":10,"description":21,"interventionNames":22},"Polidacanol and candida","will receive intralesional candida antigen injection in the largest wart and intralesional injection of (polidacanol 3%) in all warts using an insulin syringe (29 Gage × 0.5-in) every 2 weeks until complete clearance of warts or for a maximum of 6 treatment sessions",[13,18],[24,30],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","polidacanol 3%","Aethoxysklerol 3%,60mg\u002F ml ampoule, kreussler pharma, Germany",[9,20],null,{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":29},"BIOLOGICAL","candida antigen","delayed type of hypersensitivity reaction is induced toward the injected antigen and the wart virus as well. This can increase the ability of the immune system to recognize and eradicate the human papillomavirus on various parts of the body and eliminate the necessity of local treatment for each wart",[15,20],[36,41],{"name":37,"role":38,"phone":39,"phoneExt":29,"email":40},"Heba S Osman","CONTACT","01013846228","heba_shawky_post@med.sohag.edu.eg",{"name":42,"role":38,"phone":43,"phoneExt":29,"email":29},"Mohamed A Ali","01004139060",[45],{"facility":46,"status":29,"city":47,"state":29,"zip":29,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Sohag university hospital","Sohag","Egypt","EG",{"type":51,"coordinates":52},"Point",[53,54],31.69478,26.55695,{"lat":54,"lon":53},[57],{"name":58,"role":38,"phone":29,"phoneExt":29,"email":29},"Magdy M Amin, Professor",{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"PRINCIPAL_INVESTIGATOR","Heba Shawky Osman","Resident at Dermatology, Venereology, and Andrology Department Sohag University Hospital","100573698","sclerotherapy-and-candida-antigen-in-treatment-of-common-warts-100573698",false,"NCT06749665","Sclerotherapy and Candida Antigen in Treatment of Common Warts","Efficacy and Safety of Intralesional Injections of Candida Antigen, Polidocanol Sclerotherapy and Combined Candida Antigen With Polidocanol in Treatment of Patients With Common Warts","Inclusion Criteria:\n\n* Age group: \\>18years.\n* Confirmed diagnosis by clinical and dermoscopic examination of common wart will be made.\n\nExclusion Criteria:\n\n* Patients who receive any treatment for wart in the last month before the study.\n* Patients with history of renal or liver disease.\n* Patients with any evidence of bleeding diathesis, vaso-occulusive or thrombo-embolic disorders.\n* Pregnant and lactating females.\n* Patients who receive immunosuppressive therapy.\n* Patients' refusal.\n* Patients with history or evidenced hypersensitivity to any component used in this study.",true,"ALL","18 Years","60 Years",{"count":75,"type":76},75,"ESTIMATED","INTERVENTIONAL",[79],"NA","This study aims to evaluate the efficacy and safety of intralesional injections of candida antigen, polidocanol sclerotherapy and combined candida antigen with polidocanol in treatment of patients with common warts.",[82],"Common Wart","NOT_YET_RECRUITING","2024-12-24",{"date":86,"type":87},"2024-12-27","ACTUAL",{"date":89,"type":76},"2024-12-20",{"date":91,"type":76},"2025-12-01",{"name":5,"class":6},1]